CMDU

NHS Treatment Policy and National Guidelines:

• 27th January 2022 Commissioning Policy: Antivirals or neutralising monoclonal antibodies (nMABs) for non-hospitalised patients with COVID-19: https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103191
• COVID-19 Central Alerting system (For latest national guidelines): CAS - Coronavirus (COVID-19) Alerts (mhra.gov.uk)

Prescribing:

• Liverpool COVID-19 Interaction Checker : Liverpool COVID-19 Interactions (covid19-druginteractions.org)
• Blueteq Hi-Cost Drug Datbase: Hi-Cost Drugs Database Trust Edition - National (blueteq-secure.co.uk)
• SmPC Paxlovid: Paxlovid 150 mg/100 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
• SmPC Sotrovimab: Xevudy 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
• SmPC Remdesivir: Veklury 100 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
• SmPC Molnupiravir: Lagevrio 200 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)

Adult CMDU User Manuals

• CDMU Manual
• CDMU Patient Bloods
• STSFT COVID Medicines Deliver Unit (CMDU) User Manual

Adult CMDU Clinician Rota

• Consultant CMDU rota

Paediatric CMDU:

• COVID-19 - guidance for management of children admitted to hospital and for treatment of non-hospitalised children at risk of severe disease | RCPCH): https://www.rcpch.ac.uk/resources/covid-19-management-children-hospital-and-non-hospitalised

Useful Contacts

• Useful Contact Numbers/Emails